

Urogenital Tissue Engineering from bedside to bench and back:

What do clinicians need and what has basic science to offer.

Regenerative Medicine Center Utrecht*, 4-5 September 2023

Day 1, 4th of September

| Session name/Topic | Speaker | Time |
|---|---|-------|
| Registration | | 9-10 |
| Speed dating: get to know each other | Introduction and 4 rounds of 12 min | 10 |
| Clinical background | Teresa Ekerhult Frank van Aa | 11 |
| Patients perspective | Patient representative (WFIPP and/or male patient with urethral disease) | 12 |
| Basic talk on what Regenerative Medicine and Technology is, what we can do in our institute and how we can help (future) patients | RMU representative | 12.30 |
| LUNCH | | 13 |
| Urogenital tissue engineering 1: Which direction for better graft material / graft bed for urethral reconstruction | Petra de Graaf | 13.30 |
| Urogenital tissue engineering 2: Which direction for better support for pelvic floor disorders | Paul Kouwer | 14 |
| Tour through the Regenerative Medicine Utrecht Center, see the units of biofabrication, disease models, stem cells, microscopes | Multiple tour leaders (as several groups) | 14.30 |
| Break-out sessions | Participants (researchers, clinicians, and patient (representatives)) will discuss their impressions of the common needs and opportunities in regenerative medicine that were presented in the first sessions | 15 |
| Plenary discussion with integration of clinical expertise with scientific research | Panel of Magdalena Fossum, Petra de Graaf, Paul Kouwer, Frank van Aa | 16 |
| Informal diner | | 18 |



Day 2, 5th of September.

| Session name/Topic | Speaker | Time |
|--|---|-------|
| Disease and disease models | | 10 |
| Urogenital anatomy: are humans unique? | Petra de Graaf | 10 |
| Advantages and limitations of animal models | Federico Soria | 10.30 |
| One medicine: Fostering human and animal health through innovative treatments | Frank van Steenbeek | 11 |
| Animal free disease models | Silvia Mihaila | 11.30 |
| Break-out sessions | Participants (researchers, clinicians, and patient (representatives)) will discuss their impressions of the advantages and limitations in the disease models presented in the sessions this morning | 12 |
| Lunch | | 13 |
| Break-out sessions | Continuation of the discussion at 12, different groups | 13.30 |
| Plenary discussion with highlights from the breakout sessions | Panel of Federico Soria, Frank van Steenbeek, Silvia Mihaila | 14.30 |
| Preparing a general overview of the indications for integration of novel scientific developments in clinical application | Chair Petra de Graaf | 15 |
| Wrap up | | 16 |
| End of the meeting | | 16.30 |

*Venue address:

Regenerative Medicine Center Utrecht
Hubrecht institute
Uppsalalaan 8
3584 CT Utrecht
The Netherlands



« This project has received funding from the European Union's Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP N° 825575"»